Rubicon Research Pvt. Ltd.

Based in Maharashtra, India, Rubicon Research specializes in pharmaceutical formulations, providing a range of specialty pharmaceuticals and drug-device combination products for regulated markets, particularly the United States. Founded in 2000 and headquartered in Mumbai, India, Rubicon Research Pvt. Ltd. focuses on pharmaceutical formulations.

The company operates under the leadership of founder Sudhir Pilgaonkar. In April 2019, General Atlantic acquired a 70% controlling stake in Rubicon from Everstone Capital Partners for INR 10 billion. This strategic move saw Everstone Capital Partners achieve a 92% internal rate of return and a 4. 5x multiple return on their investment.

Rubicon has engaged in a total of 3 deals, with the most recent deal date being April 1, 2019. To date, the company has raised a total of INR 10 billion, all through the latest round of funding, a Secondary Buyout. Rubicon Research specializes in pharmaceutical formulations, offering a diverse range of products including specialty pharmaceuticals and drug-device combination products. Their core product portfolio includes oral capsules, solutions, suspensions, syrups, tablets, ophthalmic drops, and intrathecal injections, primarily targeting healthcare needs in regulated markets.

As of March 31, 2024, Rubicon has commercialized 55 products in the United States and is actively developing a strong pipeline across various therapeutic areas by leveraging proprietary drug delivery technologies. In 2023, Rubicon Research reported revenue of INR 49,031,941. 50 and an EBITDA of INR 5,338,561. 10.

The company operates through a dual revenue model encompassing both B2B partnerships and direct sales to healthcare providers. By collaborating with early-stage and pre-clinical stage companies, Rubicon provides co-development and commercialization services, contributing positively to its revenue stream. Their active portfolio includes 69 NDAs and ANDAs, reinforcing their commitment to maintaining a robust presence in the pharmaceutical industry. Rubicon Research is focusing on expanding its product portfolio with several new products slated for launch within the next two years.

They aim to enter new geographic markets in Europe and Asia by 2025. The recent investment of INR 10 billion from General Atlantic will be utilized to support these initiatives, enhancing their research capabilities and accelerating the development of innovative pharmaceutical solutions. This strategic funding is expected to bolster their efforts in expanding into targeted regions and launching new products, thereby driving future growth.